M&T Bank Corp Acquires Shares of 38,202 MiMedx Group, Inc. (NASDAQ:MDXG)

M&T Bank Corp bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 38,202 shares of the company's stock, valued at approximately $368,000.

Other large investors have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in MiMedx Group by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock worth $16,518,000 after acquiring an additional 44,254 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in MiMedx Group by 6.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company's stock worth $8,483,000 after acquiring an additional 92,726 shares in the last quarter. Royce & Associates LP lifted its stake in MiMedx Group by 5.3% in the 3rd quarter. Royce & Associates LP now owns 972,853 shares of the company's stock worth $5,750,000 after acquiring an additional 48,539 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in MiMedx Group by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN lifted its stake in MiMedx Group by 0.8% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company's stock worth $2,100,000 after acquiring an additional 2,737 shares in the last quarter. Institutional investors own 79.15% of the company's stock.

MiMedx Group Stock Down 1.5 %

Shares of NASDAQ MDXG traded down $0.12 during mid-day trading on Tuesday, reaching $7.92. 366,929 shares of the company traded hands, compared to its average volume of 696,579. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market cap of $1.17 billion, a PE ratio of 14.40 and a beta of 1.97. The company's fifty day moving average is $8.44 and its two-hundred day moving average is $7.83. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

Remove Ads

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. The business had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now owns 440,178 shares of the company's stock, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 142,259 shares of company stock valued at $1,116,170 in the last 90 days. 1.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.